 |
| |
| Apr-12-19 | Resumed |
Janney |
Buy |
$4 |
|
| Nov-29-18 | Initiated |
Maxim Group |
Buy |
$3 |
|
| Dec-26-17 | Downgrade |
William Blair |
Outperform → Mkt Perform |
|
|
| Dec-26-17 | Downgrade |
Janney |
Buy → Neutral |
|
|
| Oct-02-17 | Resumed |
H.C. Wainwright |
Buy |
$10 |
|
| Sep-14-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$8 → $10 |
|
| Jul-19-17 | Initiated |
H.C. Wainwright |
Buy |
$10 |
|
| Jan-08-16 | Initiated |
Cantor Fitzgerald |
Buy |
|
|
| Apr-02-15 | Initiated |
FBR Capital |
Outperform |
$17 |
|
| Jun-17-14 | Initiated |
William Blair |
Outperform |
|
|
| Jun-17-14 | Initiated |
RBC Capital Mkts |
Outperform |
$12 |
|
|
|
| Apr-01-20 05:50PM | Agile Therapeutics (AGRX) Flat As Market Sinks: What You Should Know Zacks |
| Mar-23-20 04:31PM | Agile Therapeutics (AGRX) Stock Remains a Top Pick, Says Analyst TipRanks |
| Mar-18-20 08:49AM | Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options Zacks -6.18% |
| Mar-15-20 04:02PM | Weekly CFO Buys Highlight GuruFocus.com |
| Mar-03-20 03:00PM | 7 Cheap Stocks Under $7 With Massive Upside Potential Kiplinger -8.66% |
| Feb-25-20 11:41AM | Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020 GlobeNewswire |
| Feb-21-20 12:00PM | Agile Therapeutics (AGRX) Upgraded to Buy: Here's Why Zacks -13.55% |
| 11:30AM | Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year? Zacks |
| 08:35AM | Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock GlobeNewswire |
| 07:46AM | The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga |
| Feb-20-20 04:14PM | Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire |
| 04:01PM | Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire |
| Feb-14-20 06:46PM | FDA Approves Agile Therapeutics, Inc.s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin GlobeNewswire |
| Feb-12-20 09:18AM | The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga |
| Feb-11-20 08:46AM | Agile Finalizes $35M Term Loan Facility As Twirla PDUFA Date Looms Benzinga +9.73% |
| Feb-10-20 04:30PM | Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors GlobeNewswire |
| Feb-03-20 01:30PM | Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates Benzinga |
| Jan-28-20 01:48PM | 5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts Kiplinger +14.96% |
| Jan-10-20 09:33AM | The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences Zacks |
| Jan-09-20 06:19AM | Buy Multibagger Stocks as Odds of a Rally Are High in 2020 Zacks |
| Jan-07-20 10:22AM | The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold Zacks |
| Jan-06-20 08:14AM | Here's How to Play Stocks as US-Iran Tensions Mount Zacks |
| 08:00AM | Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco GlobeNewswire |
| Jan-03-20 07:55AM | The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger Benzinga |
| Jan-02-20 08:00AM | Agile Therapeutics Strengthens Commercial Leadership Team GlobeNewswire +18.80% |
| Dec-23-19 08:36AM | Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options Zacks +7.20% |
| Dec-19-19 04:05PM | Agile Therapeutics to Present at Biotech Showcase 2020 in San Francisco GlobeNewswire +6.98% |
| Dec-14-19 06:59PM | Hedge Funds Have Never Been More Bullish On Agile Therapeutics Inc (AGRX) Insider Monkey |
| Nov-15-19 10:09AM | The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga -37.39% |
| Nov-14-19 04:30PM | Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period GlobeNewswire +10.19% |
| Nov-11-19 04:40PM | RBC: 3 Stock Picks Set to Soar 30%+ TipRanks |
| Nov-05-19 06:53AM | The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga +34.83% |
| Nov-04-19 11:24AM | Agile (AGRX) Stock Surges Over 370%, Whats Next? TipRanks +31.85% |
| Oct-31-19 01:11PM | Agile Therapeutics' stock rockets nearly 4-fold after contraceptive patch Twirla gets favorable FDA committee nod MarketWatch +223.80% |
| 10:52AM | Agile Therapeutics Rallies After FDA Panel Backs Contraceptive Patch Benzinga |
| 08:34AM | Benzinga Pro's Top 5 Stocks To Watch For Thurs., Oct. 31, 2019: AAPL, FB, AGRX, X, CROX Benzinga |
| Oct-30-19 06:33PM | Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15) GlobeNewswire |
| Oct-29-19 05:24PM | Agile (AGRX): Should You Catch this Falling Knife? TipRanks -17.92% |
| 07:32AM | The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga |
| Oct-28-19 08:00AM | Agile Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire -59.32% |
| Oct-25-19 09:30AM | Is Agile Therapeutics (AGRX) Outperforming Other Medical Stocks This Year? Zacks |
| 09:00AM | Agile Therapeutics (AGRX) Upgraded to Buy: Here's What You Should Know Zacks |
| Oct-14-19 12:17AM | 3 Top Biotech Stocks With Major Catalysts in October TipRanks |
| Oct-01-19 09:44AM | The Zacks Analyst Blog Highlights: Barrett Business Services, Hibbett Sports, Construction Partners, Agile Therapeutics and Boot Barn Zacks |
| Sep-30-19 11:16PM | Penny Stocks to Buy Using Technical Analysis for October 2019 Investopedia +5.80% |
| 08:05AM | Trade Worries Resurface! Buy These 5 U.S. Stocks Now Zacks |
| Sep-25-19 08:23AM | Top Ranked Momentum Stocks to Buy for September 25th Zacks -5.45% |
| Sep-19-19 10:29AM | Zynerba Releases Data on Epilepsy Candidate, Stock Down Zacks -8.53% |
| Sep-10-19 09:00AM | Agile Therapeutics (AGRX) Upgraded to Strong Buy: Here's What You Should Know Zacks |
| Sep-06-19 07:30AM | Agile Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire +9.60% |
| Sep-05-19 10:12AM | 3 Strong Buy Biotech Stocks Ahead of FDA Verdicts SmarterAnalyst +9.65% |
| Aug-30-19 09:45AM | Agile (AGRX) Stock Could Be Ready to Break Out TipRanks |
| Aug-22-19 10:50AM | New Strong Buy Stocks for August 22nd Zacks |
| Aug-08-19 04:15PM | Agile Therapeutics Announces Full Exercise of Over-Allotment Option by Underwriters GlobeNewswire |
| Aug-02-19 09:05AM | Agile Therapeutics Announces Pricing of $12 Million Underwritten Public Offering of Common Stock GlobeNewswire -9.55% |
| Aug-01-19 04:01PM | Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire -5.17% |
| 08:00AM | Agile Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire |
| Jul-18-19 07:30AM | Agile Therapeutics Appoints Chief Financial Officer GlobeNewswire |
| Jun-24-19 04:15PM | Agile Therapeutics Announces FDA Advisory Committee Meeting for its Investigational Transdermal Low-Dose Contraceptive Patch, Twirla® (AG200-15) GlobeNewswire |
| May-22-19 07:00AM | Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla® GlobeNewswire |
| May-17-19 07:30AM | Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla® GlobeNewswire |
| May-09-19 08:00AM | Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire |
| May-03-19 08:00AM | Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting GlobeNewswire |
| May-02-19 06:56PM | Agile Therapeutics: 1Q Earnings Snapshot Associated Press |
| 04:15PM | Agile Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire |
| Mar-28-19 08:00AM | Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK GlobeNewswire |
| Mar-15-19 08:00AM | Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress GlobeNewswire |
| Mar-14-19 12:00PM | AGRX: Numerous Catalysts in 2019 Zacks Small Cap Research |
| Mar-12-19 05:52PM | Agile Therapeutics: 4Q Earnings Snapshot Associated Press +15.97% |
| 04:15PM | Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire |
| Mar-11-19 08:00AM | Agile Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire +26.32% |
| Mar-04-19 07:30AM | Agile Therapeutics Announces $7.8 Million Private Placement GlobeNewswire +19.70% |
| Feb-12-19 10:30AM | AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19 Zacks Small Cap Research +9.37% |
| Feb-11-19 07:30AM | Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane® GlobeNewswire |
| Feb-07-19 08:00AM | Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference GlobeNewswire |
| Jan-11-19 10:45AM | AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19 Zacks Small Cap Research |
| 08:38AM | The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga |
| Jan-10-19 04:15PM | Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance GlobeNewswire |
| Dec-27-18 07:25AM | Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire |
| Dec-18-18 08:00AM | Agile Therapeutics to Present at Biotech Showcase 2019 GlobeNewswire -10.77% |
| Dec-13-18 04:15PM | Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane® GlobeNewswire |
| Nov-13-18 01:32PM | Agile Therapeutics Inc (NASDAQ:AGRX): Are Analysts Optimistic? Simply Wall St. |
| Nov-05-18 01:30PM | AGRX: Awaiting Details of Adhesion Study for Twirla® Zacks Small Cap Research |
| Nov-02-18 05:12AM | Agile Therapeutics: 3Q Earnings Snapshot Associated Press +13.82% |
| Nov-01-18 04:15PM | Agile Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire +9.72% |
| Oct-24-18 08:00AM | Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) GlobeNewswire |
| Oct-23-18 08:25AM | New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Oct-22-18 08:15AM | Agile Therapeutics Gets a Path Forward for Twirla, Analysts Review and Target ACCESSWIRE -15.20% |
| Oct-16-18 08:00AM | Todays Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics ACCESSWIRE |
| Oct-10-18 11:15AM | AGRX: FDA Provides Path to NDA Resubmission for Twirla® Zacks Small Cap Research -7.63% |
| 08:00AM | Today's Research Reports on Trending Tickers: Agile Therapeutics and Horizon Pharma ACCESSWIRE |
| Oct-09-18 08:00AM | Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA GlobeNewswire +53.71% |
| Sep-14-18 10:04AM | Does Agile Therapeutics Inc (NASDAQ:AGRX) Fall With The Market? Simply Wall St. -25.36% |
| Sep-12-18 08:00AM | Todays Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX ACCESSWIRE -17.91% |
| Sep-11-18 10:35AM | New Growth Opportunities Jump for 3 Biotech Stocks in 2018 ACCESSWIRE +116.83% |
| Aug-29-18 08:10AM | Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Aug-09-18 09:45AM | AGRX: Formal Dispute Resolution Continues to Office of New Drugs Zacks Small Cap Research -5.32% |
| Aug-03-18 08:11AM | Agile Therapeutics: 2Q Earnings Snapshot Associated Press +8.58% |
| 08:00AM | Agile Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire |
| Jul-31-18 07:10AM | Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks ACCESSWIRE |
|
|
|
|
| Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | 10% Owner | Mar 13 | Buy | 1.75 | 1,000,000 | 1,750,000 | 15,919,925 | Mar 17 03:50 PM | | Reilly Dennis | Chief Financial Officer | Mar 04 | Buy | 2.35 | 25,000 | 58,750 | 25,000 | Mar 06 08:00 AM | | Reilly Dennis | Chief Financial Officer | Mar 04 | Buy | 2.32 | 50,000 | 116,000 | 59,806 | Mar 06 08:00 AM | | ALTOMARI ALFRED | Chief Executive Officer | Feb 27 | Option Exercise | 0.71 | 16,541 | 11,744 | 301,611 | Feb 27 09:27 PM | | ALTOMARI ALFRED | Chief Executive Officer | Feb 27 | Buy | 2.71 | 10,000 | 27,100 | 311,611 | Feb 27 09:27 PM | | PERCEPTIVE ADVISORS LLC | 10% Owner | Feb 25 | Buy | 3.00 | 3,000,000 | 9,000,000 | 14,919,925 | Feb 25 08:10 PM | | PERCEPTIVE ADVISORS LLC | 10% Owner | Nov 15 | Buy | 1.68 | 5,333,800 | 8,940,812 | 11,919,925 | Nov 18 07:00 PM | | PERCEPTIVE ADVISORS LLC | 10% Owner | Nov 14 | Buy | 1.69 | 435,015 | 735,175 | 6,586,125 | Nov 18 07:00 PM | | PERCEPTIVE ADVISORS LLC | 10% Owner | Oct 29 | Sale | 0.44 | 760,291 | 334,528 | 6,151,110 | Oct 31 06:30 PM | | PERCEPTIVE ADVISORS LLC | 10% Owner | Oct 28 | Sale | 0.51 | 3,815,349 | 1,945,828 | 6,911,401 | Oct 30 06:31 PM | | PERCEPTIVE ADVISORS LLC | 10% Owner | Aug 06 | Buy | 0.95 | 2,300,000 | 2,185,000 | 10,726,750 | Oct 30 06:31 PM | | ALTOMARI ALFRED | Chief Executive Officer | Jun 10 | Buy | 1.27 | 20,000 | 25,400 | 258,568 | Jun 11 04:30 PM |
|
|
|
|
|
|
